An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Adverse reactions
- Sponsors Roche
- 26 Sep 2017 Status changed from active, no longer recruiting to completed.
- 01 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 11 May 2015 Planned End Date changed from 1 May 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.